Non-Hodgkin Lymphoma News

• Beat AML: Precision Medicine Superior to SOC Precision medicine therapy proved feasible and superior to standard-of-care (SOC) chemotherapy in patients with acute myeloid leukemia in the Beat AML Master Clinical Trial.
  Medscape Medical News, November 12, 2020
• CAR T for All R/R DLBCL Patients: The Jury Is Still Out Is it time to consider chimeric antigen receptor (CAR) T-cell therapy for all relapsed/refractory diffuse large B-cell lymphoma patients? Maybe not, according to Andrew Zelenetz, MD, PhD.
  Medscape Medical News, October 28, 2020
• Upped Risk of Death From Other Causes After Hodgkin Lymphoma Compared with the general population, survivors of Hodgkin lymphoma have a significantly higher mortality risk from noncancer and cancers other than lymphomas.
  Medscape Medical News, October 27, 2020
• First-in-Class Oral EZH2 Inhibitor Effective in Two Cancers Phase 2 results hint at the power of epigenetic targets.
  Medscape Medical News, October 19, 2020
• Diagnosing Hodgkin Lymphoma in Kids Requires Biopsy, Immunohistochemistry: Guidelines The diagnosis of pediatric Hodgkin lymphoma requires an excisional or incisional biopsy and immunohistochemistry (IHC) evaluation, and its management depends largely on the clinical stage and risk group, according to new guidelines from the National Comprehensive Cancer Network (NCCN).
  Reuters Health Information, October 16, 2020
• Double-Targeted CAR-T Cell Immunotherapy Promising for Refractory Non-Hodgkin Lymphoma A novel CAR-T cell therapy for refractory B-cell non-Hodgkin lymphoma that targets both CD19 and CD20 antigens was safe and potentially effective in a feasibility study.
  Reuters Health Information, October 14, 2020
• Cancer Researchers Cross Over to COVID-19 Clinical Trials Cancer researchers are contributing to the development and repurposing of drugs for the treatment of COVID-19, particularly for cytokine storm.
  Medscape Medical News, October 13, 2020
• HIV Glasgow 2020 Once-Weekly Investigational MK-8507 Potent Even at Low Doses The non-nucleoside reverse transcriptase inhibitor is intended for use in weekly combination therapy for HIV-1 infections.
  Medscape Medical News, October 12, 2020
• 7 Things to Know About New Lymphoma Drug Tafasitamab Lymphoma specialist Ann LaCasce, MD, discusses tafasitamab-cxix, the recently approved treatment for patients with relapsed/refractory disease.
  Medscape Medical News, October 05, 2020
• HFSA 2020 Cell Therapy for Anthracycline Cardiomyopathy Safe, Feasible In a small phase 1 study, administration of allogeneic bone marrow-derived mesenchymal stromal cells was safe and feasible in patients with anthracycline-induced cardiomyopathy heart failure.
  Medscape Medical News, October 02, 2020
• Lawmakers Focus on Price of One Drug, While Others Rise Too As drug prices spiral upward, politicians in Washington, DC and in state governments across the country have sought to address the problem in limited ways, focusing mostly on one drug: insulin.
  Kaiser Health News, September 23, 2020
• Mantle Cell Lymphoma: Identifying Patients With Indolent Disease Biomarkers are key in distinguishing between high-risk and indolent cases, allowing the latter to avoid unnecessary initial treatment.
  Medscape Medical News, September 10, 2020
• Which Drug Therapy for CLL, Time-Limited or Continuous? With several different options now available for drug treatment of chronic lymphocytic leukemia (CLL), discussions have become lengthy as the choice needs to be individualized, one expert says.
  Medscape Medical News, September 09, 2020
• Hematologic Cancers Tied to More Severe COVID-19 Illness Cancer type, age, gender, and use of chemotherapy all increased the risk of severe COVID-19 infection and/or related mortality.
  Medscape Medical News, August 31, 2020
• Azacitidine + Venetoclax Combo Benefits Older Patients With AML The treatment regimen improved overall survival and remission rates with rapid responses in the tough-to-treat population of older patients with acute myeloid leukemia (AML).
  Medscape Medical News, August 12, 2020
• Cancer Patients With COVID-19 Don't Appear to Be at Higher Risk for Blood Clots Patients with cancer and COVID-19 who are in remission or not on active cancer therapy do not appear to be at increased risk of developing blood clots or venous thromboembolism, according to new data.
  Reuters Health Information, July 31, 2020
• AACR 2020 Higher Death Rate in Cancer Patients With Nosocomial COVID-19 The all-cause mortality rate in cancer patients with nosocomial COVID-19 was more than double that of patients with community-acquired COVID-19.
  Medscape Medical News, July 31, 2020
• Bayer Loses California Appeal of Roundup Verdict, but Damages Are Reduced Bayer failed to persuade a California appeals court to overturn a verdict favoring a school groundskeeper who claimed its Roundup weed killer caused his cancer but reduced the amount of damages by 74% to $20.5 million.
  Reuters Health Information, July 21, 2020
• In Remission for 10 Years: Long-term Toxicity Data on CAR T Cells After wrestling with early toxicity, one of the first patients to receive CAR T-cell therapy is still in remission after 10 years. Longer-term data are accumulating for these therapies, dubbed 'living drugs.'
  Medscape Medical News, July 21, 2020
• Bayer Bets on Science in Bid to Prevent Future Roundup Lawsuits: Legal Experts Seeking to forestall further claims, Bayer AG is taking a risky bet that an independent scientific review will ultimately show that its widely used weed killer Roundup does not cause cancer, legal experts said.
  Reuters Health Information, June 25, 2020